S.C. Sintofarm Past Earnings Performance
Past criteria checks 2/6
S.C. Sintofarm has been growing earnings at an average annual rate of 65.3%, while the Pharmaceuticals industry saw earnings growing at 9.7% annually. Revenues have been growing at an average rate of 11.3% per year. S.C. Sintofarm's return on equity is 4.6%, and it has net margins of 4.2%.
Key information
65.3%
Earnings growth rate
77.0%
EPS growth rate
Pharmaceuticals Industry Growth | 12.4% |
Revenue growth rate | 11.3% |
Return on equity | 4.6% |
Net Margin | 4.2% |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How S.C. Sintofarm makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 11 | 0 | 0 | 0 |
30 Sep 23 | 11 | 1 | 0 | 0 |
30 Jun 23 | 11 | 1 | 0 | 0 |
31 Mar 23 | 11 | 1 | 0 | 0 |
31 Dec 22 | 10 | 1 | 0 | 0 |
30 Sep 22 | 10 | 1 | 0 | 0 |
30 Jun 22 | 10 | 1 | 0 | 0 |
31 Mar 22 | 10 | 0 | 0 | 0 |
31 Dec 21 | 10 | 0 | 0 | 0 |
30 Sep 21 | 9 | 0 | 0 | 0 |
30 Jun 21 | 9 | 0 | 0 | 0 |
31 Mar 21 | 9 | 0 | 0 | 0 |
31 Dec 20 | 9 | 0 | 0 | 0 |
30 Sep 20 | 9 | 0 | 2 | 0 |
30 Jun 20 | 8 | 0 | 3 | 0 |
31 Mar 20 | 8 | 0 | 3 | 0 |
01 Jan 20 | 8 | 0 | 3 | 0 |
01 Oct 19 | 7 | 0 | 3 | 0 |
30 Jun 19 | 7 | -1 | 3 | 0 |
31 Mar 19 | 6 | -1 | 3 | 0 |
01 Jan 19 | 6 | -1 | 2 | 0 |
01 Oct 18 | 6 | -1 | 2 | 0 |
30 Jun 18 | 6 | -1 | 2 | 0 |
31 Mar 18 | 6 | -1 | 2 | 0 |
01 Jan 18 | 6 | -1 | 2 | 0 |
01 Oct 17 | 6 | 0 | 2 | 0 |
30 Jun 17 | 6 | 0 | 2 | 0 |
31 Mar 17 | 6 | 0 | 2 | 0 |
01 Jan 17 | 6 | 0 | 2 | 0 |
01 Oct 16 | 6 | 0 | 2 | 0 |
30 Jun 16 | 7 | 1 | 2 | 0 |
31 Mar 16 | 7 | 1 | 2 | 0 |
01 Jan 16 | 6 | 1 | 2 | 0 |
30 Sep 15 | 6 | 1 | 2 | 0 |
30 Jun 15 | 6 | 0 | 0 | 0 |
31 Mar 15 | 6 | 0 | 0 | 0 |
01 Jan 15 | 6 | 0 | 0 | 0 |
30 Sep 14 | 7 | 1 | 2 | 0 |
30 Jun 14 | 7 | 1 | 2 | 0 |
31 Mar 14 | 7 | 1 | 2 | 0 |
01 Jan 14 | 7 | 1 | 2 | 0 |
Quality Earnings: SINT has high quality earnings.
Growing Profit Margin: SINT's current net profit margins (4.2%) are lower than last year (6.6%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: SINT has become profitable over the past 5 years, growing earnings by 65.3% per year.
Accelerating Growth: SINT's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: SINT had negative earnings growth (-29.7%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (3%).
Return on Equity
High ROE: SINT's Return on Equity (4.6%) is considered low.